Company Profile
Phathom Pharmaceuticals
Company Overview
Committed to improving the lives of patients suffering from acid-related gastrointestinal disorders.
Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new treatments for gastrointestinal (GI) diseases. We have licensed the exclusive rights in the United States, Europe, and Canada to a potassium-competitive acid blocker (PCAB) which the company has been developing for the treatment of certain GI disorders.
We completed Phase 3 clinical trials for the treatment of Erosive GERD, Non-Erosive GERD, and H. pylori infection, respectfully, and plan to soon initiate an additional Phase 3 trial investigating a novel “As Needed” dosing regimen for patients with Non-Erosive GERD.